NovaBridge Biosciences
NBPCIK 0001778016 · Pharmaceutical Preparations · Nasdaq
- I-Mab (until 2025-10-28)
Revenue (TTM)
¥13.81M
−94.2% YoY
FY Dec 2025
Net Income (TTM)
−¥46.27M
−108.1% YoY
FY Dec 2025
EPS Diluted (TTM)
−¥0.21
−75.0% YoY
FY Dec 2025
Gross Margin
71.4%
FY Dec 2025
Operating Margin
-682.5%
FY Dec 2025
Net Margin
-335.0%
FY Dec 2025
Free Cash Flow (TTM)
−¥183.81M
FY Dec 2025
Cash
¥210.63M
FY Dec 2025
Total Debt
¥4.22M
FY Dec 2025
Shares Outstanding
265.38M sh
FY Dec 2025